PrEP introduced in the PBS: Is HIV losing the battle?

The retroviral medicine will be more affordable for Australians under Medicare.

From the 1 April, the pre-exposure prophylaxis pill (better known as PrEP) will be part of the Pharmaceutical Benefits Scheme (PBS), meaning the retroviral medicine will reduce its cost from $208 a month to $39.95 a month. This is a big step for the LGBTIQ community, who is more at risk with HIV.

While advocates and organisations welcome the new policy, they believe there is much work ahead to not only erradicate HIV in Australia, but to erradicate the stigma around the virus and to get the public sector in metropolitan and rural areas ready to spread the information about PrEP, including GPs, pharmacists, and pathology practitioners.

Download Audio

The Wire is produced in partnership by

Contributor Stations

Supporters and Program Distribution